°øÁö»çÇ×

• ´ëÇѳ»°úÇÐȸ Äڷγª19 ¹é½Å Á¢Á¾ ±Ç°í¾È
• ¿¹¹æÁ¢Á¾ Áõ¸í¼­ ¹ß±Þ ¾È³»¹® (21.6.29 ¹ßÇ¥)
• Ç÷¼ÒÆÇ°¨¼Ò¼º Ç÷ÀüÁõ Æ÷½ºÅÍ
• COVID-19 ¿¹¹æÁ¢Á¾ ÈÄ Ç÷¼ÒÆÇ °¨¼Ò¼º Ç÷ÀüÁõ °ü·Ã ¾È³»¼­ (ÀÇ·áÀοë) 1-3ÆÇ
• Äڷγª19 ¿¹¹æÁ¢Á¾ ÈÄ Ç÷¼ÒÆÇ°¨¼Ò¼º Ç÷ÀüÁõ ±³À°µ¿¿µ»ó(ÀÇ·áÀÎ ¿ë) ¾È³»
• Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19 ¿¹¹æÁ¢Á¾ ÈÄ ¹ß»ýÇÑ ½É±Ù¿° ¹× ½É³¶¿° °ü·Ã ¾È³»¼­(ÀÇ·áÀοë) ¾È³»

´õº¸±â

Çмú ³í¹®

• Post-acute COVID-19 syndrome
• Moderna 1Â÷ Á¢Á¾ ÈÄ ¹ß»ýÇÑ Allergic Reactions ¿¡ ´ëÇÑ ¹Ì±¹ CDC ¹ßÇ¥ ÀÚ·á
• ÁÖ¿ä ¹é½Å ÀÓ»ó ³í¹®µé(Updated at 2020.1.29)
• ÁÖ¿ä ¹é½Å ÀÓ»ó ³í¹®µé_2020.12.17
• ¿ªÇÐ review article (systemic review, meta analysis Æ÷ÇÔ)
• Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial (The Lancet Infectious Disease, Published: November 17, 2020)

´õº¸±â

ÀÚÁÖÇÏ´Â Áú¹®(FAQ)

• ¼Ò¾Æ COVID-19 °¨¿°ÀÇ Æ¯Â¡ ¹× ÁÖÀÇÁ¡Àº ¹«¾ùÀΰ¡¿ä?
• ÀӽźÎÀÇ COVID-19 °¨¿°¿¡ ´ëÇÑ Æ¯Â¡ ¹× ÁÖÀÇÁ¡Àº ¹«¾ùÀΰ¡¿ä? (°¨¿° À§Ç輺, žƿ¡ ¹ÌÄ¡´Â ¿µÇâ, ¼öÁ÷ °¨¿° °¡´É¼º, ¸ðÀ¯ ¼öÀ¯ µî)
• ¾î¶² »ç¶÷µé¿¡°Ô ÁßÁõ°¨¿°ÀÌ Àß ¹ß»ýÇÒ ¼ö ÀÖÀ¸¸ç ÀÌ °æ¿ì ¾î¶»°Ô Á¶½ÉÇØ¾ß Çϳª¿ä?
• ±¹³» »ç¸ÁÀÚ·á´Â ¾î¶²°¡¿ä?
• (¼öÁ¤) Ç×¹ÙÀÌ·¯½ºÁ¦ÀÇ »ç¿ëÀÌ Ä¡·á È¿°ú°¡ ÀÖ´ÂÁö¿ä?
• Áø´Ü/È®ÁøÀº ¾î¶»°Ô ÀÌ·ç¾îÁö³ª¿ä??

´õº¸±â